HMBD-002 drug product received GMP approval for release and clinical use. The drug product will be shipped to Vanderbilt ...

Key insight: As regulators rewrite the rules for anti-money-laundering compliance, they have an opportunity to create standards that will actually prevent financial crime rather than just documenting ...

AML3D continues to expand its industrial metal additive manufacturing operations across key global markets. Metal Powder Works is sharpening its focus on advanced metal powders after exiting its ...

ISLAMABAD: The Financial Action Task Force (FATF) has warned of emerging risks to economies from rising online gaming and gambling operations, while sharing new risk indicators with countries to ...

Sony’s Venom franchise has a new final destination. The studio behind the Marvel anti-hero movies is developing its first animated movie based on the character. And it has tapped Zach Lipovsky and ...

ORLANDO, Fla. — A new analysis of three decades of clinical trial data confirms that Black patients with acute myeloid leukemia (AML) have worse survival outcomes than White patients. However, ...

Acute myeloid leukemia (AML) is not hereditary, but a person may inherit gene mutations that make the condition more likely. Having a close family member with AML can also increase the risk. Acute ...

The animation industry has always been labor-intensive, blending artistry, innovation, and technology to bring stories to life. Now, a new technological shift, generative AI (genAI), is sparking ...

The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD. In part 2 of an interview ...

Lucas Kloberdanz-Dyck is a writer for Collider. He grew up creating lists, stories, and worlds, which led to his love of anime and video games. He attended Sheridan College where he earned an Honours ...

Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...